The deadline for first-round bids in healthcare giant Pfizer's sale of its Adams subsidiary was expected to be this week, but has now been extended until next month. Cadbury Schweppes looks like being the winner: although Pfizer is stalling the sale in the hope of attracting new bidders, they seem unlikely to materialise.